In Memoriam: Professor Joseph Biederman's Contributions to Child and Adolescent Psychiatry.

Objective: To provide an overview of Joe Biederman's contributions to child and adolescent psychiatry.
Method: Nine colleagues described his contributions to: psychopharmacology, comorbidity and genetics, pediatric bipolar disorder, autism spectrum disorders, Tourette's and tic disorders, clinical and neuro biomarkers for pediatric mood disorders, executive functioning, and adult ADHD.
Results: Joe Biederman left us with many concrete indicators of his contributions to child and adolescent psychiatry. He set up the world's first pediatric psychopharmacology clinic and clinical research program in child adolescent psychiatry. As a young faculty member he began a research program that led to many awards and eventual promotion to full professor at Harvard Medical School. He was for many years the most highly cited researcher in ADHD. He achieved this while maintaining a full clinical load and was widely respected for his clinical acumen.
Conclusion: The world is a better place because Joe Biederman was here.
Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Stephen V. Faraone: Over the past 3 years, Dr. Faraone received income, potential income, travel expenses, and/or research support from Aardvark, Aardwolf, AIMH, Akili, Arbor, Atentiv, Axsome, Genomind, Ironshore, Johnson & Johnson/Kenvue, Kanjo, KemPharm/Corium, Medice, Noven, Ondosis, Otsuka, Rhodes, Shire/Takeda, Sky Therapeutics, Supernus, Tris, and Vallon. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. He also receives royalties from books published by Guilford Press: Straight Talk about Your Child’s Mental Health; Oxford University Press: Schizophrenia: The Facts; and Elsevier: ADHD: Non-Pharmacologic Interventions. In addition, he is the program director of www.adhdinadults.com. Dr. Faraone is supported by the European Union’s Horizon 2020 research and innovation program under grant agreement No 965381; NIMH grants U01AR076092-01A1, 1R21MH1264940, R01MH116037; 1R01NS128535-01; Oregon Health and Science University, Otsuka Pharmaceuticals, Noven Pharmaceuticals Incorporated, and Supernus Pharmaceutical Company. Jeffrey Newcorn over the past 3 years, has received financial compensation as a consultant, advisory board member, and lecturer from Shire Pharmaceuticals (the study sponsor and manufacturer of the study drug Vyvanse (Lisdexamfetamine)). Dr. Newcorn also receives financial compensation from other companies which either develop or assess medicines used for the treatment of ADHD. Janet Wozniak, MD receives research support from PCORI, Demarest Lloyd, Jr. Foundation, and the Baszucki Brain Research Fund. In the past, Dr. Wozniak has received research support, consultation fees or speaker’s fees from Eli Lilly, Janssen, Johnson and Johnson, McNeil, Merck/Schering-Plough, the National Institute of Mental Health (NIMH) of the National Institutes of Health (NIH), Pfizer, and Shire. She is the author of the book, “Is Your Child Bipolar” published May 2008, Bantam Books. Her spouse receives royalties from UpToDate; consultation fees from Indorsia, Cozen O’Connor, Noctrix, FoxRothschild, Sterne Kessler Goldstein & Fox, Teladoc Health, Inc., and The International Law Firm of Winston & Strawn LLP; and research support from Merck, NeuroMetrix, American Regent, NIH, NIMH, the RLS Foundation, and the Baszucki Brain Research Fund. In the past, he has received honoraria, royalties, research support, consultation fees or speaker’s fees from: Emalex, Disc Medicine, Avadel, HALEO, OrbiMed, CVS, Otsuka, Cambridge University Press, Advance Medical, Arbor Pharmaceuticals, Axon Labs, Boehringer-Ingelheim, Cantor Colburn, Covance, Cephalon, Eli Lilly, FlexPharma, GlaxoSmithKline, Impax, Jazz Pharmaceuticals, King, Luitpold, Novartis, Neurogen, Novadel Pharma, Pfizer, Sanofi-Aventis, Sepracor, Sunovion, Takeda, UCB (Schwarz) Pharma, Wyeth, Xenoport, and Zeo. Gagan Joshi is supported by the National Institute of Mental Health (NIMH) of the National Institutes of Health (NIH) under Award Number K23MH100450. In 2023, he receives research support from the Demarest Lloyd, Jr. Foundation as a primary investigator (PI) for investigator-initiated studies. Additionally, he receives research support from Genentech as a site PI for multi-site trials. Dr. Joshi is also a consultant for EuMentis Theraputics. In the past 3 years, he has received speaker’s honorariums from the American Academy of Child and Adolescent Psychiatry, American Physician Institute, Asian College of Neuro-psychopharmacology, Hackensack Meridian Health, University of Colorado-Colorado Springs, and Kennedy Krieger Institute; he received research support from F. Hoffmann-La Roche Ltd. s a site PI for multi-site trial. Through Mass General Brigham Innovation, Dr. Joshi receives royalties from a licensed method for treating autism spectrum disorder. Barbara Coffey receives income, research support, or honoraria payments from: American Academy of Child and Adolescent Psychiatry, Emalex, Florida Department of Health, Galen Mental Health, Harvard Medical School /Psychiatry Academy, New Venture Fund, NIMH/NINDS, Partners Healthcare, Skyland Trail, Tourette Association of America, Zynerba. Mai Uchida has received honorarium from American Physicians Institute and Mochida Pharmaceuticals and royalties from the book “Ask The Geniuses About the Future” (Magazine House Publishing) and has consulted to Moderna and Guidepoint. Timothy Wilens receives or has received grant support from NIH(NIDA). Dr. Timothy Wilens has co/edited books: Straight Talk About Psychiatric Medications for Kids (Guilford Press), ADHD in Adults and Children (Cambridge University Press), Massachusetts General Hospital Comprehensive Clinical Psychiatry (Elsevier), Massachusetts General Hospital Psychopharmacology and Neurotherapeutics (Elsevier), and Update on Pharmacotherapy of ADHD (Elsevier Press). Dr. Wilens has a licensing agreement with Ironshore (BSFQ Questionnaire) and 3D Therapy. Dr. Wilens is Chief, Division of Child and Adolescent Psychiatry and (Co) Director of the Center for Addiction Medicine at Massachusetts General Hospital. He serves as a clinical consultant to U.S. Minor/Major League Baseball, Gavin Foundation and Bay Cove Human Services. Craig Surman has received, in his lifetime, consulting fees from Eisai, Ironshore, Kaylon, Mcneil, NLS Pharma, Neurocentria, Nutricia, Otsuka, Pfizer, Adlon/Purdue, Rhodes, Shire, Somaxon, Sunovion, Supernus, Takeda, and Teva. He has also received payments for lectures for Alcobra, Arbor, McNeil, Janssen, Janssen-Ortho, Novartis, Shire, and Reed/MGH Academy (funded by multiple companies) as well as GME CME (funded by multiple companies). Royalties have been given to Craig B. H. Surman from Berkeley/Penguin for ““FASTMINDS” How to Thrive if You have ADHD (or think you might)” and from Humana/Springer for “ADHD in Adults: A Practical Guide to Evaluation and Management.” Additionally, Dr. Surman has conducted clinical research at Massachusetts General Hospital supported by Abbot, Cephalon, Hilda and Preston Davis Foundation, Eli Lilly, Magceutics/Neurocentria, Jazz, Johnson & Johnson/McNeil, Lundbeck, Merck, Nordic Naturals, Shire, and Takeda. Thomas J. Spencer receives royalties from Cambridge University Press for book publication and from MGH Corporate Licensing for ADHD rating scales, holds a US patent (#14/027,676) for a nonstimulant treatment for ADHD (no license fees), and has a patent pending (#61/233,686) for a method to prevent stimulant abuse (no license fees).